Table 1. Antibiogram of Gram- clinical isolates by BAL samples.

	K. pneumoniae (patient #1)	K. oxytoca (patient #2)	P. aeruginosa (patient #3)	E. coli (patient #5)	A. baumannii (patient #5)	P. aeruginosa (patient #6)
Ampicillin	≥32 (R)	16 (R)	≥32 (R)	≥32 (R)	≥32 (R)	≤2 (S)
Amoxycillin/Clavulanic acid	≥32 (R)	≤2 (S)	≥32 (R)	16 (R)	≥32 (R)	4 (S)
Piperacillin/Tazobactam	64 (R)	≤4 (S)	8 (S)	64 (R)	≥128 (R)	n.d.
Cefoxitin	≤4 (S)	≤4 (S)	n.d.	≤4 (S)	n.d.	n.d.
Cefotaxime	≤1 (S)	≤1 (S)	≥64 (R)	≥64 (R)	≥64 (R)	≤1 (S)
Ceftazidime	≤1 (S)	≤1 (S)	4 (S)	16 (R)	≥64 (R)	≤1 (S)
Cefepime	≤1 (S)	≤1 (S)	2 (S)	≥64 (R)	≥64 (R)	≤1 (S)
Ertapenem	≤0.5 (S)	≤0.5 (S)	≥8 (R)	≤0.5 (S)	≥8 (R)	≤0.5 (S)
Imipenem	≤0.25 (S)	≤0.25 (S)	1 (S)	≤0.25 (S)	≥16 (R)	1 (S)
Meropenem	≤0.25 (S)	≤0.25 (S)	2 (S)	≤0.25 (S)	n.d.	≤0.25 (S)
Amikacin	≤2 (S)	≤2 (S)	≤2 (S)	4 (S)	n.d.	4 (S)
Gentamicin	≤1 (S)	≤1 (S)	≤1 (S)	≥16 (R)	≥16 (R)	≤1 (S)
Ciprofloxacin	≤0.25 (S)	≤0.25 (S)	≤0.25 (S)	≥4 (R)	≥4 (R)	≤0.25 (S)
Tigecycline	1 (S)	≤0.5 (S)	n.d.	≤0.5 (S)	2 (i.e.)	n.d.
Fosfomycin	≤16 (S)	≤16 (S)	n.d.	≤16 (S)	≥256 (R)	n.d.
Nitrofurantoin	n.d.	n.d.	n.d.	≤16 (S)	n.d.	128 (R)
Colistin	≤0.5 (S)	≤0.5 (S)	≤0.5 (S)	≤0.5 (S)	≤0.5 (S)	1 (S)
Trimethoprim/Sulfamethoxazole	≥320 (R)	≤20 (S)	n.d.	≥320 (R)	≥32 (R)	≤20 (S)

(R) = resistant; (S) = sensitive; n.d. = not determined; i.e. = insufficient evidence that the organism or group is a good target for therapy with the agent.